Any view on the surprsing price action in Zydus? Stock is down 12% despite stellar results plus news of MSCI inclusion (although it was expected since a month). It’s not even as if it is extremely overvalued (major large cap pharma are in 25-40X P/E band). While Q1 margins are non sustainable but management has guided 28-29% for entire year.
Any news on USFDA front or something expected?
| Subscribe To Our Free Newsletter |
